The National Immunisation Advisory Committee (NIAC) will decide in the coming days if it needs to issue further advice to Government about the AstraZeneca vaccine.
This follows the finding by Europe's medicines regulator that there is a possible link between the vaccine and rare blood clotting in adults.
The AstraZeneca vaccine will make up almost 21% of the four million doses due into the country over the next three months. NIAC said it will consult with EU colleagues and will consider over the coming days if it needs to issue further advice to the Department of Health in light of the decision by the European Medicines Agency (EMA).